RESUMEN
131I-metaiodobenzylguanidine (131I-MIBG) is a theranostic agent useful for treatment of neuroendocrine malignancies. In this case, a child with a Curie score of 21 was administered 17.871 GBq (483 mCi) of 131I-MIBG. The elimination half-life progressively increased from 23 h to 77 h during the 11 d that the patient was hospitalized for radiation isolation. Six weeks after the posttherapy scan, a survey with an ion-chamber device yielded readings of 0.3 µSv/h (0.03 mR/h) on contact with spinal regions that had shown increased uptake on the scan. A planar image obtained using the 131I setting and a high-energy collimator did not demonstrate any focal uptake. 123I-MIBG was administered, and the 24-h scan was of diagnostic quality, without degradation from the remaining 131I-MIBG. Additional study is needed on whether the Curie score affects elimination of 131I-MIBG and on whether the period of hospitalized radiation isolation needs to be extended.
Asunto(s)
Radioisótopos de Yodo/farmacocinética , Radioisótopos de Yodo/uso terapéutico , Tumores Neuroendocrinos/radioterapia , Radiofármacos/farmacocinética , Imagen de Cuerpo Entero/métodos , Niño , Femenino , Humanos , Radioisótopos de Yodo/orina , Cintigrafía/métodos , Radiofármacos/uso terapéutico , Radiofármacos/orinaRESUMEN
This paper presents a fast and automatic flow-based method to extract 131I from biological samples and hospital waste, previous to liquid scintillation detection. 131I is a radionuclide extensively used in Nuclear Medicine due to their beta and gamma disintegrations, whereby hospitals have to manage the associated waste generation. The automatic developed system is based on Lab-On-Valve (LOV) flow-technique exploiting Cl-resin (135â¯mg per extraction). This methodology allows performing sample extractions and measurements on the same day, since the extraction frequency takes 1.4-4 h-1, depending on the analysed sample volume, plus up to 2â¯h of measurement for each vial. 131I is retained as iodine ion and eluted with sodium sulphide 0.2â¯molâ¯L-1. The maximum sample volume that can be preconcentrated is 20â¯mL, reaching an extraction efficiency of 85⯱â¯5%. The minimum detectable activity (MDA) is 0.05 Bq, showing a precision of 7% RSD (nâ¯=â¯5). Both, biological samples (urine and saliva) and hospital waste samples can be satisfactorily analysed by the proposed system, obtaining recoveries between 90 and 110%. The developed method is then suitable to implement in hospitals, improving the surveillance of the 131I environmental release.
Asunto(s)
Análisis de Inyección de Flujo/métodos , Hospitales/provisión & distribución , Radioisótopos de Yodo/análisis , Residuos Sanitarios/análisis , Conteo por Cintilación/métodos , Humanos , Radioisótopos de Yodo/orina , Saliva/químicaRESUMEN
BACKGROUND AND OBJECTIVES: Glomerular hyperfiltration has been considered to be a contributing factor to the development of diabetic kidney disease (DKD). To address this issue, we analyzed GFR follow-up data on participants with type 1 diabetes undergoing 125I-iothalamate clearance on entry into the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications study. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a cohort study of DCCT participants with type 1 diabetes who underwent an 125I-iothalamate clearance (iGFR) at DCCT baseline. Presence of hyperfiltration was defined as iGFR levels ≥140 ml/min per 1.73 m2, with secondary thresholds of 130 or 150 ml/min per 1.73 m2. Cox proportional hazards models assessed the association between the baseline hyperfiltration status and the subsequent risk of reaching an eGFR <60 ml/min per 1.73 m2. RESULTS: Of the 446 participants, 106 (24%) had hyperfiltration (iGFR levels ≥140 ml/min per 1.73 m2) at baseline. Over a median follow-up of 28 (interquartile range, 23, 33) years, 53 developed an eGFR <60 ml/min per 1.73 m2. The cumulative incidence of eGFR <60 ml/min per 1.73 m2 at 28 years of follow-up was 11.0% among participants with hyperfiltration at baseline, compared with 12.8% among participants with baseline GFR <140 ml/min per 1.73 m2. Hyperfiltration was not significantly associated with subsequent risk of developing an eGFR <60 ml/min per 1.73 m2 in an unadjusted Cox proportional hazards model (hazard ratio, 0.83; 95% confidence interval, 0.43 to 1.62) nor in an adjusted model (hazard ratio, 0.77; 95% confidence interval, 0.38 to 1.54). Application of alternate thresholds to define hyperfiltration (130 or 150 ml/min per 1.73 m2) showed similar findings. CONCLUSIONS: Early hyperfiltration in patients with type 1 diabetes was not associated with a higher long-term risk of decreased GFR. Although glomerular hypertension may be a mechanism of kidney injury in DKD, higher total GFR does not appear to be a risk factor for advanced DKD.
Asunto(s)
Diabetes Mellitus Tipo 1/complicaciones , Diabetes Mellitus Tipo 1/fisiopatología , Nefropatías Diabéticas/etiología , Nefropatías Diabéticas/fisiopatología , Tasa de Filtración Glomerular , Adulto , Albuminuria/orina , Ensayos Clínicos como Asunto , Creatinina/sangre , Femenino , Estudios de Seguimiento , Humanos , Radioisótopos de Yodo/orina , Ácido Yotalámico/metabolismo , Masculino , Modelos de Riesgos Proporcionales , Medición de Riesgo , Factores de Tiempo , Adulto JovenRESUMEN
Sufficient thyroid iodine uptake is needed to ensure effective radioactive iodine (RAI) treatment, which is mediated by the sodium-iodide symporter (NIS). Activation of AMP-activated-protein-kinase (AMPK), leads to decreased NIS expression and thyroid iodine uptake in in vitro and animal models. Clinically relevant conditions that lead to AMPK activation include metformin use and hypocaloric conditions. Here, we aim to assess the effects of metformin and hypocaloric diet on thyroid iodine uptake in healthy volunteers. Healthy male volunteers were included and randomized. Group 1 (n = 8) received metformin, group 2 (n = 7) followed a hypocaloric diet (1500 kcal/day), superposed on a moderate iodine restriction diet; Baseline measurements included thyroid iodine-123 (I-123) uptake and TSH, fT4, T3 and rT3 levels. After two weeks, thyroid function and I-123 uptake measurements were repeated. Baseline characteristics were similar between groups. Levels of TSH and fT4 were similar after each intervention. T3 decreased after hypocaloric diet and metformin (-0.2 ± 0.19 nmol/L, p = 0.0327; respectively -0.13 ± 0.13 nmol/L, p = 0.0282), resulting in decreased T3/rT3 ratios. There was no significant difference in thyroid I-123 uptake after each intervention. In conclusion, metformin treatment and hypocaloric diet resulted in a significant decrease in T3 levels and T3/rT3 ratios in healthy volunteers, without significant effects on thyroid iodine uptake. We found no indications that metformin or hypocaloric diet will have clinically relevant effects on RAI uptake.
Asunto(s)
Dieta Reductora/métodos , Metabolismo Energético/efectos de los fármacos , Voluntarios Sanos/estadística & datos numéricos , Metformina/farmacología , Glándula Tiroides/efectos de los fármacos , Glándula Tiroides/metabolismo , Adulto , Transporte Biológico/efectos de los fármacos , Humanos , Hipoglucemiantes/farmacología , Radioisótopos de Yodo/farmacocinética , Radioisótopos de Yodo/orina , Masculino , Tirotropina/sangre , Tiroxina/sangre , Triyodotironina/sangre , Adulto JovenRESUMEN
PURPOSE: To investigate the internal exposure of nuclear medicine practitioners in South Korea. METHODS: This study selected nuclear medicine practitioners among domestic hospitals and quantitatively measured their degree of internal exposure to radioisotopes, and conducted a dose assessment based on the results. For the dose assessment, 35 nuclear medicine practitioners at seven large hospitals were selected as the measurement subjects, and the measurements were obtained using the thyroid count, total body count, and a urine sample analysis. The internal exposure was measured once every two weeks, and measurements were obtained three to 15 times according to the practitioners. RESULTS: As a result of measuring and analyzing the radionuclides with urine samples, one or more detections above the minimum detectable activity (MDA) was identified in 52 (15%) among all 340 cases for 14 of the practitioners (43%). The committed effective doses were evaluated as have a distribution of zero to 5.4 mSv, and were mostly 1 mSv or less. There were four practitioners exceeding 1 mSv based on the whole-body measurements, whose results from a urine sample analysis and thyroid monitoring all showed exposure of 1 mSv or less. All of the practitioners participated directly in the distribution and handling of radioactive sources, and none of the nurses exceeded 1 mSv. Furthermore, it was noteworthy that, among medical assistants who do not directly handle radioisotopes and are mainly involved in the transport of contaminated patients, there was one person who exceeded the whole-body measurement standard of 1 mSv. CONCLUSIONS: The committed effective dose of most nuclear medicine practitioners who participated in the survey was lower than 1 mSv. However, because the possibility of overexposure under special circumstances cannot be completely excluded, new strict radiation protection rules on the handling of open-source radioisotopes in hospitals are required for non-handling workers.
Asunto(s)
Personal de Salud , Radioisótopos de Yodo/análisis , Exposición Profesional , Tamaño de las Instituciones de Salud , Hospitales , Humanos , Radioisótopos de Yodo/orina , Medicina Nuclear , Monitoreo de Radiación , República de Corea , Glándula Tiroides/química , Imagen de Cuerpo EnteroAsunto(s)
Hipertiroidismo/metabolismo , Radioisótopos de Yodo/farmacocinética , Radiofármacos/farmacocinética , Dosificación Radioterapéutica , Adulto , Femenino , Humanos , Hipertiroidismo/tratamiento farmacológico , Radioisótopos de Yodo/uso terapéutico , Radioisótopos de Yodo/orina , Masculino , Persona de Mediana Edad , Modelos Biológicos , Dosis de Radiación , Monitoreo de Radiación , Radiofármacos/uso terapéutico , Radiofármacos/orina , Adulto JovenRESUMEN
OBJECTIVES: Radioiodine therapy could be challenging in chronic renal failure patients requiring hemodialysis. The aim of this study was to establish the effects of hemodialysis on elimination of radioiodine from the body in thyroid carcinoma patients with end-stage chronic renal failure and to determine its effects on environmental radiation dose. MATERIALS AND METHODS: Three end-stage chronic renal failure patients (four cases) diagnosed with differentiated thyroid carcinoma requiring radioiodine therapy were included in our study. Each patient was given 50-75 mCi (1850-2775 MBq) iodine-131 with 50% dose reduction. Dose rate measurement was performed at the 2nd, 24th, and 48th hour (immediately before and after hemodialysis) after radioiodine administration. The Geiger-Müller probe was held at 1 m distance at the level of the midpoint of the thorax for the dose rate measurement. RESULTS AND CONCLUSION: The effective half-life of iodine-131 for three patients was found to be 44 h. In conclusion, the amount of radioiodine excreted per hemodialysis session was calculated to be 51.25%.
Asunto(s)
Radioisótopos de Yodo/farmacocinética , Radioisótopos de Yodo/uso terapéutico , Fallo Renal Crónico/complicaciones , Fallo Renal Crónico/terapia , Diálisis Renal , Neoplasias de la Tiroides/complicaciones , Neoplasias de la Tiroides/metabolismo , Adulto , Femenino , Humanos , Radioisótopos de Yodo/orina , Cinética , Masculino , Persona de Mediana Edad , Neoplasias de la Tiroides/radioterapiaRESUMEN
IMPORTANCE: Patients who undergo radiographic studies with contrast receive an enormous bolus of iodine. This can delay subsequent use of radioactive iodine (RAI) therapy because the iodine can compete for uptake. There is a paucity of literature on the minimum interval between contrast administration and RAI therapy. OBJECTIVE: To better characterize how long it takes for the iodine load from an intravenous contrast bolus to clear from the body. DESIGN, SETTING, AND PARTICIPANTS: A prospective cohort of 21 adults undergoing intravenous contrast CT studies at a tertiary academic medical center; exclusion criteria included history of thyroid disease or thyroidectomy, history of renal insufficiency, pregnancy, and other contrast administration within 1 year. INTERVENTION: Morning urine samples were taken before the scan for analysis and then every 2 weeks thereafter for 12 weeks. RESULTS The median baseline iodine level was 135 µg/L (range, 29-1680 µg/L), and median peak level was 552 µg/L (range, 62-6172 µg/L). Median time for urinary iodine level to normalize was 43 days, with 75% of subjects returning to baseline within 60 days, and 90% of subjects within 75 days. Baseline iodine level was a significant predictor of postcontrast iodine levels. Age, sex, weight, and estimated glomerular filtration rate were not significant. CONCLUSIONS AND RELEVANCE: These results may be used for guidance on the timing of RAI use following contrast exposure. The practice at our institution is to wait 2 months and then check a 24-hour urinary iodine level. This alleviates concerns about contrast use in patients with thyroid carcinoma interfering with adjuvant radioiodine therapy.
Asunto(s)
Medios de Contraste , Radioisótopos de Yodo/orina , Yodo/orina , Tomografía Computarizada por Rayos X/métodos , Adulto , Factores de Edad , Anciano , Estudios de Cohortes , Medios de Contraste/efectos adversos , Femenino , Humanos , Infusiones Intravenosas , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Monitoreo Fisiológico/métodos , Embarazo , Estudios Prospectivos , Medición de Riesgo , Factores Sexuales , Centros de Atención Terciaria , Factores de Tiempo , Tomografía Computarizada por Rayos X/efectos adversos , Adulto JovenRESUMEN
The aim of this study was to determine the external dose rate of iodine retention as a function of time in the bodies of thyroid cancer patients during their isolation period in the hospital. Urine samples were collected at 6th, 12th, 18th, 24th h and 2nd, 3rd, 4th, 5th d from 83 patients after oral administration of (131)I and counted. The external dose rates were also simultaneously determined at the same time points. Then, it was expressed as retained radioiodine body activity versus dose rate. Effective half life calculated from urine sample measurements was found as 18.4±1.8 h within the first 24 h and 64±2.7 h between 48 and 120 h. According to this results, the external dose rate (<20 µSv h(-1)), which patients could be discharged, was achieved after 48 h for 3700 and 5550 MBq, and after 72 h for 7400 MBq of (131)I treatments.
Asunto(s)
Radioisótopos de Yodo/uso terapéutico , Radiometría/métodos , Dosificación Radioterapéutica , Neoplasias de la Tiroides/radioterapia , Adulto , Anciano , Femenino , Hospitalización , Humanos , Radioisótopos de Yodo/orina , Masculino , Persona de Mediana Edad , Glándula Tiroides/efectos de la radiación , Neoplasias de la Tiroides/orina , Factores de Tiempo , Adulto JovenRESUMEN
OBJECTIVE: Serum thyroglobulin (Tg) has been associated with a number of thyroid disorders and has been proposed as an indicator of iodine deficiency in a population. However, few studies have addressed the epidemiology of Tg in a population-based setting or in the context of exposure to radioactive iodine-131 (I-131). Our objective was to evaluate baseline levels of Tg in relation to sociodemographic characteristics, iodine status and thyroid function for individuals exposed to I-131. DESIGN: A population-based cohort assembled in Belarus following the Chornobyl accident provided demographic factors, clinical data and physiological measurements. PARTICIPANTS: Our analytical sample included 10,344 subjects of whom 7890 had no thyroid disease and 2454 had evidence of structural or functional thyroid abnormality. MEASUREMENTS: Standardized assays were used to measure serum Tg, urinary iodine, TSH and antibodies to Tg and thyroid peroxidase. Ultrasound was used to assess the presence of nodules and estimate thyroid volume. RESULTS: In the fully adjusted model, percent change in Tg was significantly increased among females, smokers and subjects of older age and Tg increased with decreasing urinary iodine concentration, increasing serum TSH and increasing thyroid volume (P-values for trend <0·0001), and presence of thyroid nodules (P < 0·05). We found a complex interaction between region of residence, rural/urban living, presence/absence of thyroid abnormalities and serum Tg (P < 0·0001). CONCLUSIONS: In residents of Belarus, serum Tg is significantly related to presence of thyroid abnormalities as well as indicators of thyroid function and iodine deficiency and, therefore, could be used to characterize the iodine status and thyroid function of individuals in the context of epidemiological study.
Asunto(s)
Tiroglobulina/biosíntesis , Enfermedades de la Tiroides/sangre , Glándula Tiroides/patología , Adolescente , Adulto , Anticuerpos/sangre , Anticuerpos/inmunología , Accidente Nuclear de Chernóbil , Niño , Estudios de Cohortes , Femenino , Humanos , Yoduro Peroxidasa/inmunología , Radioisótopos de Yodo/orina , Masculino , Análisis Multivariante , República de Belarús/epidemiología , Población Rural/estadística & datos numéricos , Factores Socioeconómicos , Tiroglobulina/inmunología , Enfermedades de la Tiroides/epidemiología , Enfermedades de la Tiroides/orina , Pruebas de Función de la Tiroides , Glándula Tiroides/metabolismo , Tirotropina/sangre , Tirotropina/metabolismo , Población Urbana/estadística & datos numéricos , Adulto JovenRESUMEN
Radioactive iodide ((131)I-) protection studies have focused primarily on the thyroid gland and disturbances in the hypothalamic-pituitary-thyroid axis. The objective of the current study was to establish (131)I- urinary excretion profiles for saline, and the thyroid protectants, potassium iodide (KI) and ammonium perchlorate over a 75 hour time-course. Rats were administered (131)I- and 3 hours later dosed with either saline, 30 mg/kg of NH(4)ClO(4) or 30 mg/kg of KI. Urinalysis of the first 36 hours of the time-course revealed that NH(4)ClO(4) treated animals excreted significantly more (131)I- compared with KI and saline treatments. A second study followed the same protocol, but thyroxine (T(4)) was administered daily over a 3 day period. During the first 6-12 hour after (131)I- dosing, rats administered NH(4)ClO(4) excreted significantly more (131)I- than the other treatment groups. T(4) treatment resulted in increased retention of radioiodide in the thyroid gland 75 hour after (131)I- administration. We speculate that the T(4) treatment related reduction in serum TSH caused a decrease synthesis and secretion of thyroid hormones resulting in greater residual radioiodide in the thyroid gland. Our findings suggest that ammonium perchlorate treatment accelerates the elimination rate of radioiodide within the first 24 to 36 hours and thus may be more effective at reducing harmful exposure to (131)I- compared to KI treatment for repeated dosing situations. Repeated dosing studies are needed to compare the effectiveness of these treatments to reduce the radioactive iodide burden of the thyroid gland.
Asunto(s)
Yodo/orina , Percloratos/uso terapéutico , Yoduro de Potasio/uso terapéutico , Compuestos de Amonio Cuaternario/uso terapéutico , Traumatismos por Radiación/prevención & control , Enfermedades de la Tiroides/prevención & control , Animales , Yodo/sangre , Yodo/farmacocinética , Radioisótopos de Yodo/sangre , Radioisótopos de Yodo/farmacocinética , Radioisótopos de Yodo/orina , Masculino , Percloratos/sangre , Percloratos/orina , Ratas , Ratas Sprague-Dawley , Glándula Tiroides/metabolismo , Tirotropina/sangreRESUMEN
Activities of (131)I and (137)Cs excreted in urine from two healthy males during May 1986, when contaminated air masses from Chernobyl arrived on the territory of the Czech Republic, were determined by bioassay. The data were used to estimate the intakes and committed effective doses from these radionuclides. The results for inhalation intakes are of particular interest, in the absence of sufficient contemporary data for airborne activity. They are found to be higher than initial estimates based on air sampling.
Asunto(s)
Contaminantes Radiactivos del Aire/análisis , Radioisótopos de Cesio/orina , Accidente Nuclear de Chernóbil , Radioisótopos de Yodo/orina , Modelos Biológicos , Dosis de Radiación , Monitoreo de Radiación/métodos , Carga Corporal (Radioterapia) , Simulación por Computador , Humanos , Masculino , Persona de Mediana Edad , Centrales Eléctricas , Liberación de Radiactividad Peligrosa , UcraniaRESUMEN
CONTEXT: Tyrosine kinase inhibitors (TKI) are used for the treatment of various cancers. Case reports and clinical trials have reported abnormal thyroid function tests (TFT) after treatment with sunitinib, imatinib, sorafenib, dasatinib, and nilotinib. An increased requirement for levothyroxine was reported in thyroidectomized patients during TKI treatment. OBJECTIVE: We hypothesized that abnormal TFT are compatible with inhibition of thyroid hormone (TH) transporters and subsequently reduced pituitary-TH feedback. Monocarboxylate transporter 8 (MCT8) is a TH transmembrane transporter in brain, pituitary, and other organs. MCT8 mutation leads to abnormal TFT in patients and respective mouse models. We tested whether TKI are able to inhibit MCT8-mediated TH uptake into cells. DESIGN: Madin-Darby-canine kidney (MDCK1) cells stably expressing human MCT8 were exposed in vitro to TKI at increasing concentrations, and MCT8-mediated [(125)I]T(3) uptake and efflux were measured. The mode of inhibition was determined. RESULTS: TKI exposure dose-dependently inhibited MCT8-dependent T(3) and T(4) uptake. IC(50) values for sunitinib, imatinib, dasatinib, and bosutinib ranged from 13-38 µm, i.e. similar to the Michaelis-Menten constant K(m) for T(3) and T(4), 4 and 8 µm, respectively. Kinetic experiments revealed a noncompetitive mode of inhibition for all TKI tested. CONCLUSIONS: Partial inhibition by TKI of pituitary or hypothalamic TH feedback may increase TSH or increase the levothyroxine requirement of thyroidectomized patients. It is still possible that other mechanisms contribute to TKI-mediated impairments of TFT, e.g. altered metabolism of TH. Bosutinib was not previously reported to alter TFT.
Asunto(s)
Transportadores de Ácidos Monocarboxílicos/fisiología , Inhibidores de Proteínas Quinasas/farmacología , Proteínas Tirosina Quinasas/antagonistas & inhibidores , Triyodotironina/metabolismo , Animales , Benzamidas , Unión Competitiva , Transporte Biológico/efectos de los fármacos , Células Cultivadas , Ensayos Clínicos como Asunto , Perros , Regulación hacia Abajo/efectos de los fármacos , Evaluación Preclínica de Medicamentos , Humanos , Mesilato de Imatinib , Indoles/farmacología , Radioisótopos de Yodo/farmacocinética , Radioisótopos de Yodo/orina , Transportadores de Ácidos Monocarboxílicos/genética , Transportadores de Ácidos Monocarboxílicos/metabolismo , Piperazinas/farmacología , Proteínas Tirosina Quinasas/metabolismo , Pirimidinas/farmacología , Pirroles/farmacología , Sunitinib , Simportadores , Tiroxina/metabolismo , Tiroxina/farmacocinética , Tiroxina/orina , Transfección , Triyodotironina/farmacocinética , Triyodotironina/orinaRESUMEN
In nuclear medicine, estimating the radioactivity contained in the urine of patients treated with I and discharged to the environment could prevent the exposure of a population to radioactive effluents and the pollution of the aquatic environment with ionizing radiation. This can be a regulatory requirement (as in Spain) or requested by the sewer authority. Seventy-nine differentiated thyroid cancer cases (undergone as inpatients) and 187 hyperthyroidism cases (undergone as outpatients) were treated in our hospital with I throughout the year 2009. In hyperthyroidism treatments, the effective elimination constant was used to calculate the corresponding discharged activity in the urine, giving an activity level always below 0.7 GBq. In differentiated thyroid cancer treatments, patient's urine was collected in storage tanks during the hospitalization. Measurements of external exposure at 1 m made every day were used to calculate the activity contained in the urine. The tank activity was always below 15 GBq, but always higher than 2 GBq. Obtained results show that effective doses to sewage workers, received from liquid discharges, can only be reduced to less than 10 µSv if storage tanks are installed. Without tanks, 157 µSv can be reached, above the constrain dose used in nuclear installations (100 µSv). Our calculations may be helpful to the regulatory authority to review the clinical radiation waste normative, especially in countries where the discharges are released directly into public sewage plants.
Asunto(s)
Hipertiroidismo/radioterapia , Radioisótopos de Yodo/uso terapéutico , Radioisótopos de Yodo/orina , Aguas del Alcantarillado/química , Neoplasias de la Tiroides/radioterapia , Humanos , Hipertiroidismo/metabolismo , Radioisótopos de Yodo/administración & dosificación , Aguas del Alcantarillado/análisis , Neoplasias de la Tiroides/metabolismo , Factores de TiempoRESUMEN
BACKGROUND: Current knowledge about Chornobyl-related thyroid cancer risks comes from ecological studies based on grouped doses, case-control studies, and studies of prevalent cancers. OBJECTIVE: To address this limitation, we evaluated the dose-response relationship for incident thyroid cancers using measurement-based individual iodine-131 (I-131) thyroid dose estimates in a prospective analytic cohort study. METHODS: The cohort consists of individuals < 18 years of age on 26 April 1986 who resided in three contaminated oblasts (states) of Ukraine and underwent up to four thyroid screening examinations between 1998 and 2007 (n = 12,514). Thyroid doses of I-131 were estimated based on individual radioactivity measurements taken within 2 months after the accident, environmental transport models, and interview data. Excess radiation risks were estimated using Poisson regression models. RESULTS: Sixty-five incident thyroid cancers were diagnosed during the second through fourth screenings and 73,004 person-years (PY) of observation. The dose-response relationship was consistent with linearity on relative and absolute scales, although the excess relative risk (ERR) model described data better than did the excess absolute risk (EAR) model. The ERR per gray was 1.91 [95% confidence interval (CI), 0.43-6.34], and the EAR per 104 PY/Gy was 2.21 (95% CI, 0.04-5.78). The ERR per gray varied significantly by oblast of residence but not by time since exposure, use of iodine prophylaxis, iodine status, sex, age, or tumor size. CONCLUSIONS: I-131-related thyroid cancer risks persisted for two decades after exposure, with no evidence of decrease during the observation period. The radiation risks, although smaller, are compatible with those of retrospective and ecological post-Chornobyl studies.
Asunto(s)
Accidente Nuclear de Chernóbil , Radioisótopos de Yodo/toxicidad , Neoplasias Inducidas por Radiación/epidemiología , Enfermedades de la Tiroides/epidemiología , Neoplasias de la Tiroides/epidemiología , Adolescente , Adulto , Estudios de Cohortes , Relación Dosis-Respuesta en la Radiación , Femenino , Humanos , Yoduro Peroxidasa/sangre , Radioisótopos de Yodo/orina , Masculino , Persona de Mediana Edad , Neoplasias Inducidas por Radiación/cirugía , Distribución de Poisson , Estudios Prospectivos , Liberación de Radiactividad Peligrosa , Tiroglobulina/sangre , Enfermedades de la Tiroides/cirugía , Glándula Tiroides/efectos de la radiación , Glándula Tiroides/cirugía , Neoplasias de la Tiroides/inducido químicamente , Neoplasias de la Tiroides/cirugía , Tirotropina/sangre , Factores de Tiempo , Ucrania/epidemiología , Adulto JovenRESUMEN
This study evaluated biokinetic behavior of radioiodine in the bodies of ten female adult patients, with well-differentiated thyroid cancer, treated with 131I post-near total thyroidectomy, for ablation of remnant thyroid. In vivo and in vitro bioassay analyses were performed from the first hour following radioiodine administration until minimum detection limits were reached. The retention of 131I in the body from day 1 to day 6 after the intake may be mathematically represented by an exponential decreasing curve, with an average biological half-life of approximately 0.81 d, with the exception of patients who presented thyroiditis. From day 6 to day 13, urinary excretion rates indicated an increased liberation of iodine. After 2 wk, the body retention of iodine followed an exponential decrease, with a half-life of about 15 d. The average whole-body dose for these patients was 0.27 Gy, as estimated through cytogenetic techniques.
Asunto(s)
Técnicas de Ablación , Citogenética , Radioisótopos de Yodo/farmacocinética , Radioisótopos de Yodo/uso terapéutico , Neoplasias de la Tiroides/radioterapia , Neoplasias de la Tiroides/cirugía , Tiroidectomía , Adulto , Anciano , Femenino , Semivida , Humanos , Radioisótopos de Yodo/orina , Persona de Mediana Edad , Dosis de Radiación , Neoplasias de la Tiroides/metabolismo , Resultado del TratamientoRESUMEN
Soon after the Bravo nuclear test at Bikini Atoll in the Marshall Islands on 1 March 1954, urine samples were collected for analysis of excreted radioactivity from native residents exposed to radioactive fallout on two atolls as well as from U.S. military personnel on a third atoll. The earliest acquired samples, obtained by the Los Alamos Scientific Laboratory (LASL), were assayed for various radionuclides and provided the first known measurements of (131)I in urine following exposure to fallout from a nuclear test. Over the course of 1954, many additional samples were collected by the LASL, as well as by the Atomic Energy Commission New York Operations Office's Health and Safety Laboratory and the Naval Radiological Defense Laboratory. Collectively, the groups sampled included Marshallese exposed on Rongelap and Ailinginae Atolls, American military weather observers temporarily resident on Rongerik Atoll, and sailors from the Japanese fishing vessel, the Lucky Dragon. While the bioassay measurement data and individual urine volumes have been crucial to various attempts to assess intakes of radioactivity and the related internal radiation doses among the Marshallese, those data have never been published in any peer-reviewed journal, but have been restricted to agency memoranda, laboratory reports, and summaries in some publications and book chapters. Reconstructions of internal doses to Marshallese in 1954 and in later years have depended on these data and, hence, they have considerable historical importance as well as importance to ongoing health risk projections for Marshallese. This paper presents much of the original data on urine volumes and radioactivity from the various assays of urine for radionuclides, and compares estimates of (131)I intakes made in 1954, 1985, 1987, and 2008.
Asunto(s)
Armas Nucleares , Monitoreo de Radiación , Ceniza Radiactiva/análisis , Radioisótopos/orina , Adulto , Bioensayo , Niño , Geografía , Humanos , Radioisótopos de Yodo/efectos adversos , Radioisótopos de Yodo/metabolismo , Radioisótopos de Yodo/orina , Micronesia/epidemiología , Dosis de Radiación , Ceniza Radiactiva/efectos adversos , Radioisótopos/efectos adversos , Radioisótopos/metabolismo , Medición de Riesgo , Factores de TiempoRESUMEN
Cholecystokinin, produced in the proximal small intestine, is a short acting satiating peptide hormone. CCK-10, before and after mono-iodination, was previously coupled to 10kDa polyethylene glycol (PEG). The formed conjugates PEG10kDa-CCK-10 and PEG10kDa-[(127)I]-CCK-10 show after i.p. administration to rats a sustained food intake reduction during 8h in comparison to 2h for free CCK-10. The present study examined the blood pharmacokinetics of this pharmacological interesting molecule by means of PEG10kDa-[(123)I]-CCK-10 following intravenous, intraperitoneal, intramuscular and nasal administration and the biodistribution after i.p. administration. HPLC analysis with radiometric detection allowed the differentiation between inorganic iodide and the intact tracer in blood. Blood kinetics after i.v. injection was fitted to a bi-exponential with a distribution half-life of 15 min and with an elimination half-life of 8 hours for intact PEG10kDa-[(123)I]-CCK-10. The biodistribution studies showed a higher accumulation of the tracer for all administration routes in organs expressing CCK receptors localized in the gastrointestinal tract such as pancreas, duodenum and small intestine. No indication of blood brain barrier crossing for the conjugate could be observed independently of the administration route. Main clearance was via the urinary pathway.
Asunto(s)
Colecistoquinina/sangre , Portadores de Fármacos/farmacocinética , Radioisótopos de Yodo/sangre , Fragmentos de Péptidos/sangre , Polietilenglicoles/farmacocinética , Animales , Colecistoquinina/administración & dosificación , Colecistoquinina/orina , Vías de Administración de Medicamentos , Portadores de Fármacos/administración & dosificación , Portadores de Fármacos/síntesis química , Portadores de Fármacos/química , Semivida , Radioisótopos de Yodo/orina , Masculino , Fragmentos de Péptidos/administración & dosificación , Fragmentos de Péptidos/orina , Polietilenglicoles/administración & dosificación , Polietilenglicoles/química , Ratas , Ratas Wistar , Distribución TisularRESUMEN
BACKGROUND: Low-iodine diet is prescribed before (131)I administration in patients with differentiated thyroid cancer, although no study has properly quantified its clinical benefit. OBJECTIVE: Our study aimed to evaluate the association between urinary iodine excretion (UIE) and (131)I ablation by correlating UIE with the rate of successful ablation. PATIENTS: We retrospectively studied 201 differentiated thyroid cancer patients who had received (131)I therapy and posttherapy whole-body scan (WBS) for remnant ablation after either thyroid hormone withdrawal (THW group, n = 125) or recombinant human TSH (rhTSH group, n = 76). The outcome of thyroid ablation was assessed using two different criteria: no visible uptake at control WBS 8-12 months after ablation or no visible uptake plus undetectable stimulated serum thyroglobulin (Tg). RESULTS: According to the criterion of no visible uptake, 84.6% of the patients were successfully ablated, with no significant difference between THW and rhTSH groups. Mean UIE at the time of ablation was 132 +/- 160 microg/liter, not significantly different between patients of the THW and rhTSH groups. There was no significant difference in UIE between ablated or nonablated patients both in the whole group and the rhTSH or THW groups. According to the criterion of no visible uptake plus undetectable stimulated serum Tg (in anti-Tg negative patients) at control WBS 8-12 months after ablation, UIE was not significantly different in ablated and nonablated patients. CONCLUSIONS: Our study indicates that the body iodine content is not an important determinant of thyroid ablation, when preparing the patients with either THW or rhTSH.
Asunto(s)
Carcinoma/radioterapia , Radioisótopos de Yodo/uso terapéutico , Radioisótopos de Yodo/orina , Neoplasias de la Tiroides/radioterapia , Adolescente , Adulto , Anciano , Carcinoma/diagnóstico , Carcinoma/patología , Carcinoma/orina , Niño , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neoplasia Residual/diagnóstico , Pronóstico , Neoplasias de la Tiroides/diagnóstico , Neoplasias de la Tiroides/patología , Neoplasias de la Tiroides/orina , Resultado del Tratamiento , Adulto JovenRESUMEN
The follow-up and treatment of thyroid cancer presents several aspects subject to discussion, such as its management in patients with End-Stage Renal Failure (ESRF). We present a patient with ESRF and papillary thyroid carcinoma, which had to be coordinated among different departments (Endocrinology, Nuclear Medicine, Nephrology and Physics and Radiation Protection). Both the diagnostic scintigraphy with (123)I and the ablative treatment with (131)I performed later were performed with the administration of rh TSH. The room in which the metabolic therapy was to be performed was prepared for the patient's periodic hemodialysis. The (131)I dose used was 80% of the usual dose. This made it possible to assure the therapeutic effect and that the patient's stay in hospital would only be for 5 days. Throughout the whole diagnostic and therapeutic process, no adverse effects attributable to rh TSH or radioiodine were observed. The coordination among the departments involved enabled an effective and safe process for the patient.